CME

This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Rapid Response from Austin: Expanding Options in Type 2 Diabetes Management

Rapid Response from Austin: Expanding Options in Type 2 Diabetes Management

This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Overview

Author(s)/Faculty: Carol H. Wysham, MD; John E. Anderson, MD; Guillermo E. Umpierrez, MD, CDE, FACP, FACE
Source: Healio - Endocrinology Education Lab
Type: VideoArticles/Items: 3
Release Date: 5/24/2017Expiration Date: 5/23/2018
Credit Type: CMENumber of Credits: 0.75
Cost: FreeProvider: Vindico Medical Education
Approximately 150 million people worldwide have diabetes mellitus and this number is expected to double by 2025. Numerous therapeutic advances have emerged, including oral and injectable pharmacologics as well as novel insulin analogs. However, many patients continue to experience poor glycemic control. This Rapid Response activity will highlight the latest evidence from the 2017 American Association of Clinical Endocrinologists (AACE) 26th Annual Scientific & Clinical Congress on the efficacy and safety of new and emerging formulations of insulin, including insulin-based injectable combination therapies, as well as review evidence-based guidelines regarding insulin treatment targets and intensification.

CME Information

page 1 of 6